Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAISY: Phase 3 anifrolumab study in systemic sclerosis
CTR20233932Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anifrolumab in systemic sclerosis (SSc), sponsored by AstraZeneca. Started Jun 2024; status: active.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on CTR20233932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233932.